『Unraveled』のカバーアート

Unraveled

Unraveled

著者： Dana-Farber Cancer Institute
無料で聴く

Unraveled is a podcast produced by Dana-Farber that explores the mysteries of the science of cancer. In Seasons 1 and 2, veteran broadcaster Ken Shulman digs into the cutting-edge science that is transforming cancer research and providing hope for scientists and cancer patients. In Season 3, our researchers take center stage to share stories of their science in their own words, so you can directly hear about the wonder and excitement of their discoveries and how they could inspire new treatments for patients with cancer.Copyright 2021 Dana-Farber Cancer Institute 450 Brookline Avenue, Boston, MA 02215 化学 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Season 3 Episode 1: Advances in Endometrial Cancer Research

    Season 3 Episode 1: Advances in Endometrial Cancer Research
    2026/09/01
    Cigall Kadoch had a hunch that the research in her lab might be relevant to endometrial cancer research. She had spent more than a decade studying the molecular machinery that unwinds DNA in the nucleus of a cell to make the right DNA instructions readable by the cell at the right time. This machinery – the SWI/SNF or BAF complex – is altered by gene mutations in about 20 percent of cancers, including an aggressive form of endometrial cancer. The discovery of that connection, and the collaborative translational research done with gynecologic oncologist Jessica St. Laurent, MD, at Dana-Farber to determine if an inhibitor targeting these complexes could benefit patients with endometrial cancer — it’s the story we’re sharing in this episode of Unraveled Presents: Conversations About Cancer. Episode Notes: The Nature Genetics paper detailing Kadoch's and St. Laurent's findings: https://www.nature.com/articles/s41588-025-02333-9 The Dana-Farber story: https://blog.dana-farber.org/insight/2025/10/dana-farber-research-uncovers-potential-targeted-therapy-for-endometrial-cancer/ Clarification of facts and sources: Colorectal and uterine cancer are, respectively, the third and fourth most common cancers in women as of 2026, each affecting 7% of women: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf
    続きを読む 一部表示
    20 分
  • Season 2 Episode 6: Big Data, AI, and Cancer Research

    Season 2 Episode 6: Big Data, AI, and Cancer Research
    2023/05/17
    As our universe of knowledge expands, sometimes incrementally and more often, exponentially, its new dimensions create new challenges. The more we know, the better our tools are, the more choices we have. And that's great, but it's hard to distill mountains of patient data, clinical trials, therapies, discoveries, and a boatload of externalities. Hard to distill all of these into the best possible research and care. Oh, and don't forget the human genome in its almost infinite complexity. It can be overwhelming when you try to think about it absent, sort of having some help. But what kind of human mind could provide that help? Could it be that the help we need, the intelligence we need isn't human at all.
    続きを読む 一部表示
    28 分
  • Season 2 Episode 5: With a Little Help From My Friends: Combination Immunotherapy

    Season 2 Episode 5: With a Little Help From My Friends: Combination Immunotherapy
    2023/04/26
    If there is such a thing as a holy grail in cancer research, a secret spell or golden ring that can ward off any and all forms of the disease, it probably lives somewhere in the realm of immunotherapy. A new category of immunotherapy drugs, called checkpoint inhibitors, take the brakes off the immune system and let the T cells do their job: attack cancer. They've been approved for more than 25 different types of cancer.  However, the average response rate for checkpoint inhibitors is 20 to 30%, which means that it's not working for 70% of the people who take it. So that's the project now: to extend the benefits of immunotherapy to all cancer patients, instead of to just a few. And the best way to do that, it seems, is by doubling down, by pairing immunotherapy with other therapies so patients can benefit from both. Sound logical? Sure. Sound easy? Not on your life. It's called combination immunotherapy, and it's what this episode of Unraveled is about.
    続きを読む 一部表示
    32 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません